What is Surrozen?
Surrozen is a biotechnology company dedicated to discovering and developing novel drug candidates that selectively modulate the Wnt signaling pathway. The company's core innovation lies in its development of tissue-specific antibodies designed to harness the body's inherent biological repair mechanisms. These therapies hold potential applications across a broad spectrum of disease areas, including inflammatory bowel disease, hepatitis, various eye diseases, hearing loss, lung and airway conditions, and certain neurological disorders. Surrozen's strategic focus on engaging endogenous repair processes positions it at the forefront of regenerative medicine, aiming to address unmet medical needs with precision-engineered biologics.
How much funding has Surrozen raised?
Surrozen has raised a total of $308M across 4 funding rounds:
Series A
$33M
Series B
$50M
Series C
$50M
Share Placement
$175M
Series A (2017): $33M with participation from The Column Group
Series B (2019): $50M led by The Column Group
Series C (2020): $50M supported by Hartford Healthcare Trust, The Column Group, and Horizons Ventures
Share Placement (2025): $175M, investors not publicly disclosed
Key Investors in Surrozen
The Column Group
The Column Group (TCG) is a venture ecosystem focused on advancing scientific innovation in the life sciences sector. With a history of funding key advancements in biotechnology, TCG has supported the formation and growth of 55 companies, generating $4.0 billion in returns for its partners. TCG employs an edge-to-edge investment model that nurtures early-stage technology platforms and later-stage programs, ensuring comprehensive support from inception to exit. The firm is dedicated to mentoring CEOs and fostering collaboration within its ecosystem to maximize success in therapeutic breakthroughs.
Horizons Ventures
Horizons Ventures is an investment firm that has been supporting entrepreneurs in turning startup ventures into successful companies for over 20 years. They partner with visionary entrepreneurs, providing both equity financing and active involvement to foster growth and innovation.
Hartford Healthcare Trust
Undisclosed investor participating in the funding round.
What's next for Surrozen?
With the recent infusion of $175M in a major strategic investment, Surrozen is poised to accelerate its development pipeline and expand its clinical programs. The substantial enterprise-level funding, totaling $308M, provides the necessary resources to advance its tissue-specific antibody candidates through rigorous clinical trials and towards potential commercialization. This strategic backing is expected to fuel further research into the Wnt pathway and its therapeutic applications, solidifying Surrozen's position as a key player in the biotechnology sector. The company's trajectory suggests a focus on scaling operations and potentially exploring new therapeutic targets within its regenerative medicine framework.
See full Surrozen company page
